Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00966641 · ClinicalTrials.gov registry record · Phase 1
Oral Bioequivalence Study of PL 3100 and Naproxen in Healthy Adults
A Phase 1 study, sponsored by PLx Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT00966641 is a Phase 1 study that has completed, run by PLx Pharma. The registered enrollment target is 34 participants.
The verdict
NCT00966641, a Phase 1 study, has completed, sponsored by PLx Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the single-dose pharmacokinetics of the investigational drug PL 3100 following oral administration to healthy volunteers and to compare the pharmacokinetic profiles of PL 3100 and naproxen at a prescription dose.
Interventions
- DRUG Naproxen
- DRUG PL 3100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2009-08 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00966641
The ClinicalTrials.gov registry entry for NCT00966641 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PLx Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Naproxen is the first listed.
NCT00966641 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00966641 about?
NCT00966641 is a clinical study titled "Oral Bioequivalence Study of PL 3100 and Naproxen in Healthy Adults". The purpose of this study is to determine the single-dose pharmacokinetics of the investigational drug PL 3100 following oral administration to healthy volunteers and to compare the pharmacokinetic profiles of PL 3100 and naproxen at a prescription dose.
What is the current status of trial NCT00966641?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2009-08. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00966641?
The interventions under investigation include: Naproxen (DRUG), PL 3100 (DRUG).
Who is sponsoring clinical trial NCT00966641?
This trial is sponsored by PLx Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.